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Effects of CD2-associated protein deficiency on
amyloid-β in neuroblastoma cells and in an APP
transgenic mouse model
Fan Liao1, Hong Jiang1, Subhashini Srivatsan2, Qingli Xiao3, Katheryn B Lefton4, Kaoru Yamada5, Thomas E Mahan4,
Jin-Moo Lee3, Andrey S Shaw2 and David M Holtzman1*

Abstract
Background: CD2-associated protein (CD2AP) is an SH3-containing scaffold adaptor protein which regulates the
actin cytoskeleton. Recently, CD2AP was identified as a genetic risk factor for Alzheimer’s disease (AD) by several
genome-wide association studies. One of the hallmarks of AD is the accumulation of aggregated forms of Amyloid-β
(Aβ) in the brain. In humans, CD2AP AD susceptibility locus (rs9349407) is associated with an increased plaque burden.
Aβ production is highly regulated by endocytosis and is influenced by lysosomal function. Lysosomal trafficking is
influenced by CD2AP. In this study, we decreased CD2AP levels in N2a neuroblastoma cultures and PS1APP mice and
analyzed Aβ levels and plaque burden.
Results: Our data show that suppressing CD2AP expression using shRNA in N2a-APP695 cells results in decreased cell
membrane amyloid precursor protein, decreased Aβ release and a lower Aβ42/Aβ40 ratio. CD2AP protein is expressed
in the brain as detected by western blot, and the expression level is dependent on gene dosage. In 1-month old
PS1APP mice, complete loss of CD2AP in brain resulted in a decreased Aβ42/Aβ40 ratio in brain tissue lysates while there
was no effect on Aβ deposition or accumulation in PS1APP mice expressing one copy of CD2AP.
Conclusion: CD2-Associated Protein affects Aβ levels and Aβ42/Aβ40 ratio in vitro. The effect of CD2-Associated Protein
on Aβ metabolism is subtle in vivo.
Keywords: CD2AP, Alzheimer’s disease, Amyloid-β

Background
CD2-associated protein (CD2AP) was originally identified
as a scaffold protein required for organization of the
immunological synapse - the specialized interface between
a T lymphocyte and an antigen-presenting cell [1]. It was
later shown that CD2AP, by virtue of its multiple
protein-protein binding modules, interacts with multiple
proteins involved in diverse biological processes. These
associations have implicated CD2AP in receptor tyrosine
kinase internalization, actin cytoskeleton remodeling and
vesicular trafficking [2].
Alzheimer’s disease (AD) is a neurodegenerative disorder
characterized by the impairment of memory and other
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cognitive functions as well as the presence of extracellular
amyloid plaques and intracellular neurofibrillary tangles
[3]. There is substantial evidence indicating that amyloid-β
(Aβ) plays an essential role in the development of AD [4,5].
The deposition of Aβ into amyloid plaques is dependent
on the concentration of brain interstitial fluid Aβ [6],
which is regulated by endocytosis [7]. Recently CD2AP
was detected as a risk factor for AD by several genomewide association studies [8-10]. In a yeast model for cellular toxicity elicited by Aβ, a functional homolog of CD2AP
[11] was identified as a suppressor of Aβ toxicity [12]. In
addition, a recent study in humans suggests that CD2AP
AD susceptibility locus (rs9349407) is associated with
increased plaque burden [13]. However, the relationship
between CD2AP and Aβ has never been reported in
mammalian cells or in mouse models expressing human
amyloid precursor protein (APP)/Aβ.

© 2015 Liao et al.; licensee BioMed Central. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
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Since the reported AD susceptibility locus (rs9349407)
which has impact on plaque load in humans [13] is in the
CD2AP gene, we asked whether manipulating CD2AP
expression level affects Aβ levels. In the current study, we
knocked down CD2AP expression in N2a-APP695 cells
and observed a decrease in Aβ levels as well as the ratio of
Aβ42/Aβ40 in the cell culture medium. We crossed
CD2AP knockout mice with PS1APP mice and observed a
reduction of Aβ42/Aβ40 in the brain tissue. Due to the fact
that CD2AP knockout mice have glomerular disease and
do not survive beyond a few months of age until plaque
onset in PS1APP mice [14], we also measured the effects
of CD2AP haploinsufficiency on amyloid plaque deposition.
There was no effect of CD2AP haploinsufficiency on Aβ
deposition up to 7 months of age.

Results and discussion
Effects of CD2AP deficiency in cultured N2a-APP695 cells

APP processing is regulated by endocytosis. Given that
CD2AP plays an important role in regulating endocytosis,
we first tested whether CD2AP has an effect on Aβ
synthesis or Aβ release in cultured cells. We used CD2AP
shRNA to knockdown CD2AP levels (Figures 1, 2A) in
neuroblastoma N2a-APP 695 cells and measured Aβ in
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the cell lysates and Aβ released into the cell culture
medium. The results showed that CD2AP sh RNA1 (Sh1)
significantly decreased both Aβ40 and Aβ42 secreted into
the culture medium by about 20 ~ 30% (Figure 1A,B)
while the Aβ40 and Aβ42 in cell lysates were not affected
(Figure 1D,E). CD2AP sh2 had greater effects on the
Aβ42 in the medium as compared to CD2AP sh1
(Figure 1A,B). The Aβ40 and Aβ42 in cell lysates were
increased about 30% by CD2AP sh2 (Figure 1D,E).
Interestingly, both CD2AP sh1 and CD2AP sh2
decreased the Aβ42/ Aβ40 ratio in cell culture medium
(Figure 1C). However, the Aβ42/ Aβ40 ratios in cell lysates
were unaltered (Figure 1F). We further examined the total
APP and APP on the cell surface in these N2a cells. The
results showed that CD2AP sh1 and sh2 did not change
total APP levels in N2a cells (Figure 2B,D). However,
membrane APP levels were decreased by CD2AP sh1
and sh2 (Figure 2B,C). In cells, nascent APP is posttranslationally modified and transported from the
endoplasmic reticulum to the plasma membrane [15]. To
be proteolytically cleaved into Aβ, APP must be internalized
from the cell surface into the cell and transported to
endosomes where β-secretase and γ-secretase complexes
cleave APP to produce Aβ [7,16]. In the current study,

Figure 1 CD2AP shRNAs decreased extracellular Aβ levels in cell culture. N2a-695 cells were transfected with CD2AP shRNAs or control
shRNA. (A-C) Aβ40, Aβ42 and Aβ42/Aβ40 ratio in the cell culture medium. (D-F) Aβ40, Aβ42 and Aβ42/Aβ40 ratio in the cell lysates (n = 5/group;
*, p < 0.05, **, p < 0.01, ***, p < 0.001, one-way ANOVA followed by Tukey test).
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Figure 2 CD2AP shRNAs decreased cell membrane APP. (A) CD2AP and actin levels in cells transfected with CD2AP shRNAs or control
shRNA. (B) Membrane and total APP levels in the cells transfected with CD2AP shRNAs or control shRNA. (C-D) Quantification of membrane APP
and total APP in H (n = 3/group, *, p < 0.05, Student’s t-test).

knocking down CD2AP in N2a-APP695 cells may
decrease APP on cell surface which would result in less
APP getting into endosomes and less Aβ being released
into cell culture medium.
Expression of CD2AP in the brain

Before we studied the effects of CD2AP on Aβ pathology
in vivo, we first determined whether CD2AP is expressed
in the brain and whether the expression level correlates
with CD2AP gene dosage. Using western blot, we detected
CD2AP in CD2AP+/+ brains with CD2AP−/− brains serving
as a negative control (Figure 3A). As reported in the kidney
[17], CD2AP protein level in the brains of mice with
CD2AP haploinsufficiency (CD2AP+/−) is about 50% of the
level in CD2AP+/+ mice (Figure 3B).

PS1APP/CD2AP−/−, respectively, p < 0.05, Student’s t-test)
and males (0.35 ± 0.015 vs 0.30 ± 0.010 for PS1APP/
CD2AP+/+ vs PS1APP/CD2AP−/−, respectively, p < 0.05,
Student’s t-test).
Although inhibiting CD2AP expression levels in cultured
cells resulted in decreased levels of Aβ in the cell culture
medium, we did not observe changes in the absolute concentration of cortical Aβ42 or Aβ40 in CD2AP knockout

Effects of CD2AP knockout on brain Aβ levels in 1-month
old PS1APP mice

Next, we assessed whether CD2AP has similar effects on
Aβ levels and Aβ42/Aβ40 ratio in vivo. If CD2AP affects
Aβ production or release, we would expect to see the
changes in young mice before plaque deposition. Therefore,
we generated 1-month old PS1APP/CD2AP+/+ (female,
n = 6; male, n = 6) and PS1APP/CD2AP−/− (female, n = 7;
male, n = 5) mice and measured Aβ40 and Aβ42 levels in
the PBS soluble fraction of cortical tissue. The results
showed that there were no significant changes in the
absolute concentration of Aβ40 and Aβ42 (Figure 4A,B).
However, the ratio of Aβ42/Aβ40 was lower in PS1APP/
CD2AP−/− mice as compared to PS1APP/CD2AP+/+
mice (Figure 4C). This effect was similar in both females
(0.37 ± 0.008 vs 0.29 ± 0.0025 for PS1APP/CD2AP+/+ vs

Figure 3 CD2AP protein was expressed in the brain. (A) Western
blot for CD2AP and tubulin in cortices from CD2AP−/−, CD2AP+/− and
CD2AP+/+ mice. (B) Quantification of CD2AP levels in CD2AP+/− and
CD2AP+/+ mice in western blot presented in A. (n = 3/group, **, p < 0.01,
Student’s t-test).
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Figure 4 Effects of CD2AP on Aβ levels in 1-month old PS1APP mice. PS1APP/CD2AP+/+ (n = 12 total, 6 females and 6 males) and
PS1APP/CD2AP−/− (n = 12 total, 7 females and 5 males) mice were sacrificed at 1-month of age. The cortices were homogenized in PBS. Aβ40 (A), Aβ42
(B) and Aβ42/ Aβ40 (C) ratio were measured. (**, p < 0.01, Student’s t-test).

PS1APP mice as compared to PS1APP mice expressing
two copies of CD2AP. While Aβ levels in cultured
APP-expressing N2a-APP695 cells are mainly determined
by APP processing, Aβ levels in vivo are regulated not
only by Aβ production and release but also Aβ uptake and
degradation by different cell types, Aβ clearance mediated
by interstitial fluid (ISF) and cerebrospinal fluid (CSF)
bulk flow and Aβ transport across the blood brain barrier.
Among these mechanisms, many of them are regulated
by vesicular trafficking, which can be influenced by
manipulating CD2AP levels. For example, disruption of
endocytosis in neurons inhibits APP processing and
reduces Aβ levels [7]. On the other hand, disruption of
endocytosis in the microglia or astrocytes could result in
an increase of extracellular Aβ due to decreased Aβ
uptake and degradation [18]. Therefore, these effects
could theoretically cancel each other out when knockout of CD2AP occurs in all the cell types. This may
explain why we did not observe the same change in
Aβ concentration in vivo as we have seen in vitro.
In cultured N2a-APP695 cells, knocking down CD2AP
resulted in a lower Aβ42/Aβ40 ratio. Similar changes also
occurred in the soluble Aβ42/Aβ40 ratio in 1-month old
PS1APP/CD2AP−/− mice as compared to PS1APP/
CD2AP+/+ mice. The ratio of Aβ42/Aβ40 is determined
by γ-secretase cleavage of APP. Mutations of presenilin,
an active enzymatic component of the γ-secretase complex, lead to autosomal dominant familial AD [19,20]
likely in large part due to an increased Aβ42/Aβ40 ratio.
On the other hand, mutations in APP [21] or gamma
secretase modulators [22] can influence γ-secretase cleavage
and alter the Aβ42/Aβ40 ratio. Some molecules such as
phosphatidylinositol clathrin assembly lymphoid-myeloid
leukemia (PICALM) shift the Aβ42/Aβ40 ratio through
affecting internalization of γ-secretase [23]. In the current
study, the change of Aβ42/Aβ40 ratio occurred before plaque
deposition, suggesting CD2AP knockout could affect the
selective production of Aβ40 and Aβ42. Since CD2AP
binds membrane proteins, it could affect Aβ cleavage

by interacting with γ-secretase complex, by modifying
APP directly or through some intermediary molecules
to shift the ratio of Aβ42/Aβ40. It is shown recently
that a homolog of Nephrin, a protein interacting with
CD2AP [14], is required for γ-secretase mediated
Notch and APP-like cleavages in Drosophila [24].
Effects of CD2AP haploinsufficiency on amyloid
deposition in 7-month old PS1APP mice

Shifting the ratio of Aβ42/Aβ40 results in an altered time
course of plaque deposition in both humans [19,20] and
mice [25]. Since we observed changes in the Aβ42/Aβ40
ratio in cultured cells and 1-month old PS1APP mice, we
next asked whether CD2AP deficiency affects amyloid
plaque load in older PS1APP mice. CD2AP−/− mice have
a ~ 6-week life-span due to renal failure [14] while the
average plaque onset age in PS1APP mice is at ~4-month.
Therefore, we were not able to assess plaque deposition in PS1APP/CD2AP−/− mice. Mice with CD2AP
haploinsufficiency (CD2AP+/−) live a normal life span
but express ~50% less CD2AP in the brain compared
to CD2AP+/+ mice (Figure 3A,B). We therefore asked
whether a ~50% reduction of CD2AP levels affects Aβ
pathology in PS1APP mice. We generated PS1APP/
CD2AP+/− and PS1APP/CD2AP+/+ mice and characterized their Aβ pathology at the age of 7-months. We first
measured Aβ levels in the cortical tissue lysates. The
results showed no difference in the absolute level of Aβ40
and Aβ42 in the PBS (soluble forms of Aβ), Triton or
Guanidine (insoluble forms of Aβ) brain fractions
between PS1APP/CD2AP+/− and PS1APP/CD2AP+/+
groups (Figure 5). In the PBS soluble fraction, the
Aβ42/Aβ40 ratio in the female PS1APP/CD2AP+/− group
was significantly lower than that in female PS1APP/
CD2AP+/+ group (p < 0.05, Student’s t-test). However, the
effects on males tended to trend in the opposite direction
(Figure 5). In the Triton and Guanidine fractions, there
was no change in the Aβ42/Aβ40 ratio associated with
CD2AP gene status (Figure 5).
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Figure 5 Effects of CD2AP haploinsufficiency on tissue Aβ levels in 7-month old PS1APP mice. PS1APP/CD2AP+/+ (n = 19 total, 10 females
and 9 males) and PS1APP/CD2AP+/− (n = 18 total, 9 females and 9 males) mice were sacrificed. Aβ40, Aβ42 and Aβ42/Aβ40 ratio in PBS fraction, 1%
triton fraction and Guanidine fraction (*, p < 0.05, Student’s t-test).

To determine whether CD2AP haploinsufficiency affects
the morphology or other properties of the Aβ plaques, we
stained the tissue with biotinylated anti-Aβ1–13 monoclonal antibody HJ3.4B (Figure 6A) or Thioflavin S
(Figure 6C) which stains fibrillar forms of Aβ plaques.
We did not observe any significant changes in plaque
distribution, individual plaque size or plaque morphology
associated with CD2AP gene status. We further quantified
the% area covered with plaques in the cortex. The results
demonstrated that neither Aβ immunostained plaques
(Figure 6B) nor fibrillar plaques (Figure 6D) were
different in mice with CD2AP haploinsufficiency.
Taken together, although CD2AP haploinsufficiency
lowered the Aβ42/Aβ40 ratio in PBS fraction of female
PS1APP mice, the majority of our data demonstrate that
CD2AP haploinsufficiency did not cause changes in Aβ
accumulation.
For certain genes that have clear effects on Aβ metabolism and deposition such as apolipoprotein E or PICALM,

a 50% reduction of expression has significant effects on
Aβ pathology [26,27]. However, in our in vivo studies,
lowering of CD2AP expression levels by 50% in the
PS1APP/CD2AP+/− mice did not affect Aβ pathology as
assessed by biochemical or histological methods as compared to that in control PS1APP/CD2AP+/+ mice at the
age of 7-months. It is possible that expression of 50% the
level of CD2AP is sufficient to maintain adequate CD2AP
function in the brain. In the future, additional work
on CD2AP conditional knockout mice which live a
longer life-span can be done to verify the effects of
CD2AP on amyloid deposition in mice expressing
lower than levels found in C2DAP haploinsufficiency
in the brain.

Conclusions
In summary, we demonstrated that knocking down
CD2AP in cultured N2A-APP695 cells reduces Aβ40, Aβ42
and the ratio of Aβ42/Aβ40 released into cell culture
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Figure 6 Effects of CD2AP haploinsufficiency on Aβ plaque deposition in 7-month old PS1APP mice. PS1APP/CD2AP+/+ (n = 19 total, 10
females and 9 males) and PS1APP/CD2AP+/− (n = 18 total, 9 females and 9 males) mice were sacrificed. (A) Representative images for Aβ staining
in PS1APP/CD2AP+/+ and PS1APP/CD2AP+/− cortex (Scale bar =400 μm). (B) Quantification of Aβ plaque load in PS1APP/CD2AP+/+ and PS1APP/
CD2AP+/− cortex. (C) Representative images of Thioflavin S staining in PS1APP/CD2AP+/+ and PS1APP/CD2AP+/− cortex (Scale bar =400 μm).
(D) Quantification of fibrillar plaque load in PS1APP/CD2AP+/+ and PS1APP/CD2AP+/− cortex.

medium. CD2AP expression is readily detectable in the
brain and so we extended out in vitro studies to an APP
mouse model. In 1-month old PS1APP mice, a complete
loss of CD2AP reduced the Aβ42/Aβ40 ratio in the cortical
tissue but the absolute levels of Aβ40 and Aβ42 were
unaltered. In 7-month old PS1APP mice, CD2AP
haploinsufficiency did not cause significant changes
in Aβ pathology as analyzed by biochemical and
histological assays. In the future, conditional knockout of
CD2AP in different brain cells can be produced to further
confirm or refute the effects of CD2AP on Aβ pathology.
Primary neurons cultured from PS1APP/CD2AP−/− mice
need to be used to confirm the in vitro effects of CD2AP
on Aβ production and release. Besides Aβ plaques,
another hallmark of AD is the accumulation of insoluble
tau protein in structures such as intracellular neurofibrillary tangles. It was found that RNAi targeting Cindr, the
fly ortholog of the human CD2AP, enhances tau toxicity
in a Drosophila model in a recent study [28]. Therefore,
CD2AP could also modify AD status by interacting with
tau or potentially via other mechanisms. In the future,
additional possible mechanisms should be explored to
establish the mechanism(s) underlying the role of CD2AP
in AD pathogenesis.

Methods
Animals

APPswe/PS1ΔE9 (PS1APP) mice overexpressing a
chimeric mouse/human APP695 Swedish gene and
human PSEN1 with an exon 9 deletion on a B6C3
background [25] were crossed with CD2AP+/− mice
on B6 background [14] to generate PS1APP/CD2AP+/−
and PS1APP/CD2AP+/+ (control) mice. To generate
PS1APP/CD2AP−/− and PS1APP/CD2AP+/+ (control)
mice, the PS1APP/CD2AP+/− mice were crossed with
CD2AP+/− /nephrin Tg mice. The nephrin Tg mice
express CD2AP driven by mouse nephrin promoter
which directs expression specifically in podocytes
[29]. On the day of harvesting, the mice were perfused with ice-cold PBS containing 0.3% heparin. For
the 7-month old PS1APP/CD2AP+/− and PS1APP/
CD2AP+/+ mice, one hemibrain was fixed in 4%
paraformaldehyde for immunohistochemistry. The
other hemibrain was dissected and flash-frozen on
dry ice for biochemical assays. For all other animals,
both sides of the brain were dissected for biochemical assays. All experimental protocols were approved
by the Animal Studies Committee at Washington
University.
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CD2AP knockdown in cultured cells

N2a-APP695 cells were grown in DMEM/Opti-MEM
(50:50) supplemented with 5% FBS and 200 μg/ml of
G418. Control (firefly luciferase target sequence, fLuc;
GCTTACGCTGAGTACTTCGA) and two different
CD2AP-specific shRNA duplexes (CD2AP target sequences,
CD2AP sh1 and sh2: GTGGAACCCTGAACAATAAG and
GGAACCAATGAAGATGAACTTACA, respectively) were
cloned into the pFLRu lentivirus as previously described
[30]. Viral supernatants were generated in 293 T cells by
transfection of the lentiviral plasmids with Lipofectamine
2000 (Invitrogen) and the packaging plasmids as described.
Pooled supernatants, harvested at 24 and 48 hours
post-transfection, were applied to N2a cells with 8ug/ml
polybrene and spun at room temperature for 2 hours at
2000 rpm. Supernatants were replaced with fresh medium
immediately after centrifugation. To confirm the knock
down of CD2AP, the level of CD2AP protein in RIPA cell
lysates was assessed by western blot using a rabbit
anti-CD2AP polyclonal antibody [1]. Actin was detected
using a mouse monoclonal antibody (Sigma) which served
as internal control. The cells were then cultured in a
12-well plate in serum free medium at a density of
80%. After 8 hrs, the cell culture medium was collected
and the cells were homogenized in RIPA buffer. The Aβ40
and Aβ42 in the cell culture medium and cell lysates
were measured by sandwich ELISA. All the values
were normalized to the protein concentration in the
cell lysate to correct for the differences caused by
different cell numbers in each well. To assess total
APP and membrane APP, N2a-fluc, N2a-sh1 and N2a
sh2 cells were cultured in a 6-well plate at a density
of 90%. The membrane proteins were biotinylated by
incubating the cells with EZ-Link Sulfo-NHS-SS-Biotin
(Thermo Scientific) on ice for 30 min. Then the cells were
homogenized in lysate buffer containing 50 mM
Tris–HCl, pH 7.5, 150 mM NaCl, 1% (v/v) Nonidet
P-40, 0.5% (w/v) deoxycholate, and 1× protease inhibitor
mixture [27]. Total APP in the cell lysates was assessed
using western blot with a rabbit anti-APP polyclonal
antibody (Zymed). The value was normalized to actin
in the same lysates. Cell lysates containing same amount
of total protein were incubated with Dynabeads® MyOne™
Streptavidin T1 (Invitrogen) to pull down biotinylated
membrane protein. Western blot for APP was performed
on the pull-down products to assess the membrane APP.
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of Health). The levels of CD2AP were normalized using
tubulin values from the same sample.
ELISA

For 1-month old PS1APP/CD2AP−/− and PS1APP/
CD2AP+/+ (control) mice, brain cortices were homogenized in PBS in the presence of 1× protease inhibitor mixture (Roche). For 7-month old PS1APP/CD2AP+/− and
PS1APP/CD2AP+/+ mice, brain cortices were sequentially
homogenized with cold PBS, 1% Triton, and 5 M guanidine
buffer in the presence of 1× protease inhibitor mixture.
The levels of Aβ40 and Aβ42 were measured by sandwich
ELISA. For Aβ40 or Aβ42, anti-Aβ35–40 HJ2 or anti-Aβ37–42
HJ7.4 were used as capture antibodies, and anti-Aβ13–28
HJ5.1-biotin [6] was used as detecting antibody.
Immunohistochemistry

Serial coronal sections at 50-μm thickness were collected
from the rostral to the caudal end of each brain hemisphere
using a freezing sliding microtome (Leica). Aβ plaques were
immunostained using biotinylated anti-Aβ1–13 monoclonal
antibody HJ3.4B [31].
Thioflavine S staining

For fibrillar plaques, brain sections were stained with
0.025% Thioflavin S (Sigma) in 50% ethanol for 10 min.
Then the sections were washed with 50% ethanol twice
followed by PBS [32].
Imaging

Immunostained brain sections were scanned using a
Nanozoomer slide scanner (Hamamatsu Photonics).
Quantitative analysis of immunopositive staining was
performed as previously described [33]. Briefly, images
of immunostained sections were exported with NDP
viewer (Hamamatsu Photonics), converted to 8-bit
grayscale using ACDSee Pro 2 software (ACD Systems)
and threshold was set to highlight positive staining and
analyzed using ImageJ (National Institutes of Health).
3 sections per mouse (Bregma, −1.4 mm caudal to
Bregma, −2.0 mm caudal to Bregma) were quantified
(the cortex immediately dorsal to the hippocampus)
and the average was used to represent each mouse.
Statistics

Western blot for CD2AP in brain lysates

Four-week old CD2AP+/+, CD2AP+/− and CD2AP−/− mice
were perfused with ice-cold PBS containing 0.3% heparin.
The cortices were dissected and homogenized in RIPA
buffer. CD2AP was detected by western blot using a rabbit
anti-CD2AP polyclonal antibody [1]. The western blot
bands were quantified using image J (National Institutes

Two-tailed Student’s t-test was used to determine if
there were significant differences between two groups
unless otherwise specified. One-way ANOVA was used to
compare differences among 3 or more groups followed by
Tukey post-test unless otherwise specified. Data in all the
figures are expressed as mean ± S.E.M unless otherwise
specified.
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